AMENDMENTS TO THE CLAIMS

Claim 1 (currently amended)

A compound selected from the group consisting of all possible isomeric forms and their mixtures, a compound of the formula



I

either R_1 is hydrogen or methyl and R_2 is selected from the group consisting of cyclohexyl substituted by an amine, $-CH_2-CH_2NHCH_3$,



$-CH_2CHCH_3NH_2$,



$-CHCH_3CH_2NH_2$, -(CH2)aOH where a is an integer of 1 to 8, -(CH_2) B-C≡N where b is an integer of 1 to 8, $-CHCH_3C_6H_5$, $-(CH_2)$-$C(CH_3)_2NHCOCF_3$, and $-CHCH_3(CH_2)dOH$ where d is an integer of 1 to 8

or R_1 and R_2 together with the nitrogen to which they are attached form a ring of 3, 4 or 5 carbons optionally substituted by an amine

R_3 is selected from the group consisting of hydrogen, methyl and hydroxyl

R_4 is hydrogen or hydroxyl,

R is selected from the group consisting of alkyl and cycloalkyl of up to 30 carbon atoms, optionally containing at least one heteroatom, at least one heterocycle and alkyl or cyclic acyl of up to 30 carbon atoms optionally containing at least one heteroatom, and~~/or~~ at least one heterocycle,

T is selected from the group consisting of hydrogen, methyl, $-CH_2CONH_2$, $-CH_2$=N, and $-(CH_2)_2NH_2$ ~~and $-(CH_2)_2N(alk)^+X^-$, X is halogen and alk is alkyl of up to 8 carbon atoms~~,

Y is selected from the group consisting of hydrogen, hydroxyl, halogen and $-OSO_3H$ or a salt thereof,

W is hydrogen or OH,

Z is hydrogen or methyl and its non-toxic, pharmaceutically acceptable acid addition salt.

Claim 2 (currently amended)

~~A~~ The compound of claim 1 in which T is hydrogen.

Claim 3 (currently amended)

~~A~~ The compound of claim 1 in which W is hydrogen.

Claim 4 (currently amended)

~~A~~ The compound of claim 1 in which Z is methyl.

Claim 5 (currently amended)

~~A~~ The compound of claim 1 in which Y is hydrogen.

Claim 6 (currently amended)

~~A~~ The compound of claim 1 in which R_3 is methyl.

Claim 7 (currently amended)

~~A~~ The compound of claim 1 in which R_4 is hydroxyl.

Claim 8 (currently amended)

~~A~~ The compound of claim 1 in which R is selected from the group consisting of



































and



Claim 9 (currently amended)

~~A~~ The compound of claim 8 in which R is



Claim 10 (currently amended)

~~A~~ The compound of claim 8 in which R is



Claim 11 (currently amended)

~~A~~ The compound of claim 1 in which R_1 is hydrogen.

Claim 12 (currently amended)

~~A~~ The compound of claim 1 in which R_2 is



Claim 13 (currently amended)

~~A~~ The compound of claim 1 in which R_2 is selected from the group consisting of



and



~~and~~



Claim 14 (currently amended)

~~A~~ The compound of claim 1 in which R_2 is



or



Claim 15 (currently amended)

~~A~~ The compound of claim 1 selected from the group consisting of

- 1-[4-[[(1H-benzimidazol-2-yl)-methyl)-amino-N2-[[4"-(pentyloxy) [1,2':4', 1"-

terphenyl]-4-yl]-carbonyl]-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]5-L-serine-echinocandine B trifluoroacetate (isomer B), and

- trans 1-[4-[(2-aminocyclo-hexyl)-amino]-N2-[[4"(pentyloxy) [1,1':4', 1"-terphenyl]-4-yl-carbonyl]-L-ornithine]-4-[4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandine B trifluoroacetate (isomer A).

Claim 16 (currently amended)

A process for the preparation of a compound of claim 1 comprising reacting a compound of the formula



(II)

wherein R, R_3, R_4, T, Y, W and Z are defined as in claim 1 with an amine or amino ~~derivative~~ compound capable of introducing

R1
/
-N in which R_1 and R_2
\
R2

are defined as in claim 1 and optionally to the action of a reducing agent

and/or an amine functionalization agent,

and/or an acid to form the salt of the product of claim 1,

and/or a separation agent of the different isomers obtained.

Claims 17 and 18 (cancelled)

Claim 19 (currently amended)

An antifungal composition comprising an antifungally effective amount of a compound of claim ~~1~~ 15 and an inert pharmaceutical carrier.

Claim 20 (currently amended)

A method of treating fungal infections in warm-blooded animals comprising administering to warm-blooded animals in need thereof an antifungally effective amount of a compound of claim ~~1~~ 15.